Author

J. D. Hebert

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 4 Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 2 Approach:genetic perturbation / CRISPR· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

L. Andrejka· 4 shared M. M. Winslow· 4 shared C. W. Murray· 2 shared D. A. Petrov· 2 shared D. Petrov· 2 shared G. Boross· 2 shared H. Cai· 2 shared M. K. Tsai· 2 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

L. Andrejka

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Efficient and multiplexed somatic genome editing with Cas12a mice

J. D. Hebert, H. Xu, Y. J. Tang, P. A. Ruiz, C. R. Detrick, J. Wang, N. W. Hughes, O. Donosa, L. Andrejka, S. Karmakar, I. Aboiralor, R. Tang, J. Sage, L. Cong, D. Petrov, M. M. Winslow

This study develops transgenic Cas12a mice to enable efficient, multiplexed somatic genome editing for studying complex genetic interactions in vivo.

bioRxiv · Mar 7, 2024Cancer Biology

Combinatorial in vivo genome editing identifies widespread epistasis during lung tumorigenesis

J. D. Hebert, Y. J. Tang, L. Andrejka, S. S. Lopez, D. A. Petrov, G. Boross, M. M. Winslow

The paper uses in vivo genome editing to study genetic interactions in lung cancer, finding widespread negative epistasis among tumor suppressor genes.

bioRxiv · Mar 7, 2024 · PreprintCancer Biology

Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities

M. Yousefi, G. Boross, C. Weiss, C. W. Murray, J. D. Hebert, H. Cai, E. L. Ashkin, S. Karmakar, L. Andrejka, L. Chen, M. Wang, M. K. Tsai, W.-Y. Lin, C. Li, P. Yakhchalian, , M. M. Winslow

This study identifies RAS/PI3K pathway activation as a common driver in oncogene-negative lung adenocarcinomas and shows these tumors are vulnerable to targeted therapy.

bioRxiv · Oct 20, 2021Cancer Biology

Multiplexed identification of RAS paralog imbalance as a driver of lung cancer growth

R. Tang, E. G. Shuldiner, M. Kelly, C. W. Murray, J. D. Hebert, L. Andrejka, M. K. Tsai, N. W. Hughes, M. I. Parker, H. Cai, Y.-C. Li, G. Wahl, R. Dunbrack, P. K. Jackson, D. Petrov, M. M. Winslow

This study identifies HRAS and NRAS as suppressors of KRASG12D-driven lung cancer using CRISPR screens in mouse models and confirms their role in human cell lines.

bioRxiv · Jul 8, 2021 · PreprintCancer Biology